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Summary
Background Findings from the RESTART trial suggest that starting antiplatelet therapy might reduce the risk of 
recurrent symptomatic intracerebral haemorrhage compared with avoiding antiplatelet therapy. Brain imaging 
features of intracerebral haemorrhage and cerebral small vessel diseases (such as cerebral microbleeds) are associated 
with greater risks of recurrent intracerebral haemorrhage. We did subgroup analyses of the RESTART trial to explore 
whether these brain imaging features modify the effects of antiplatelet therapy.
Methods RESTART was a prospective, randomised, open-label, blinded-endpoint, parallel-group trial at 122 hospitals 
in the UK that assessed whether starting antiplatelet therapy might reduce the risk of recurrent symptomatic 
intracerebral haemorrhage compared with avoiding antiplatelet therapy. For this prespecified subgroup analysis, 
consultant neuroradiologists masked to treatment allocation reviewed brain CT or MRI scans performed before 
randomisation to confirm participant eligibility and rate features of the intracerebral haemorrhage and surrounding 
brain. We followed participants for primary (recurrent symptomatic intracerebral haemorrhage) and secondary 
(ischaemic stroke) outcomes for up to 5 years (reported elsewhere). For this report, we analysed eligible participants 
with intracerebral haemorrhage according to their treatment allocation in primary subgroup analyses of cerebral 
microbleeds on MRI and in exploratory subgroup analyses of other features on CT or MRI. The trial is registered with 
the ISRCTN registry, number ISRCTN71907627.
Findings Between May 22, 2013, and May 31, 2018, 537 participants were enrolled, of whom 525 (98%) had 
intracerebral haemorrhage: 507 (97%) were diagnosed on CT (252 assigned to start antiplatelet therapy and 
255 assigned to avoid antiplatelet therapy, of whom one withdrew and was not analysed) and 254 (48%) underwent 
the required brain MRI protocol (122 in the start antiplatelet therapy group and 132 in the avoid antiplatelet therapy 
group). There were no clinically or statistically significant hazards of antiplatelet therapy on recurrent intracerebral 
haemorrhage in primary subgroup analyses of cerebral microbleed presence (2 or more) versus absence (0 or 1) 
(adjusted hazard ratio [HR] 0·30 [95% CI 0·08–1·13] vs 0·77 [0·13–4·61]; pinteraction=0·41), cerebral microbleed number 
0–1 versus 2–4 versus 5 or more (HR 0·77 [0·13–4·62] vs 0·32 [0·03–3·66] vs 0·33 [0·07–1·60]; pinteraction=0·75), or 
cerebral microbleed strictly lobar versus other location (HR 0·52 [0·004–6·79] vs 0·37 [0·09–1·28]; pinteraction=0·85). 
There was no evidence of heterogeneity in the effects of antiplatelet therapy in any exploratory subgroup analyses 
(all pinteraction>0·05).
Interpretation Our findings exclude all but a very modest harmful effect of antiplatelet therapy on recurrent 
intracerebral haemorrhage in the presence of cerebral microbleeds. Further randomised trials are needed to replicate 
these findings and investigate them with greater precision.
Funding British Heart Foundation.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Cere bral small vessel diseases cause, or contribute to, the 
majority of stroke due to intracerebral haemorrhage. 
Combinations of the many imaging biomarkers on brain 
CT and MRI can identify cerebral small vessel diseases 
such as cerebral amyloid angiopathy with reasonable 
accuracy.1–3
Some brain imaging features of intracerebral haem­
orrhage and cerebral small vessel diseases are associ­
ated with a higher risk of intracerebral haemorrhage 
recurrence in general, and in people taking antiplatelet 
therapy.4–8 For example, the proportional increase in the 
risk of intracerebral haemorrhage recurrence is up to five­
times higher after lobar versus non­lobar haemorrhage,8 
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up to six­times higher with presence versus absence of 
cerebral microbleeds on MRI,7 and roughly four­times 
higher with presence versus absence of superficial 
siderosis on MRI.6 Consequently, guidelines and opin­
ions suggest that location of intracerebral haemorrhage 
and some features of cerebral small vessel diseases 
can guide therapeutic decisions.9–12 However, dec isions 
about antiplatelet therapy for patients with intracere­
bral haemorrhage and cerebral microbleeds are mainly 
informed by two analyses of a single­centre small 
observational cohort study of survivors of intra cerebral 
haem orrhage,5,13 one of which found an up to five­times 
greater risk of recurrent lobar intracerebral haemorrhage 
associated with use of aspirin in people with cerebral 
microbleeds.5
A randomised controlled trial is the most reliable test of 
overall treatment effects and enables estimation of 
hetero geneity in the effects of treatment in primary 
subgroup analyses (informed by previous evidence), 
as well as in other exploratory subgroup analyses.14 
One randomised trial found no heterogeneity by MRI 
features in the effects of aspirin and clopidogrel versus 
aspirin alone on stroke recurrence in 1278 adults after 
subcortical ischaemic stroke,15 and two other trials found 
no heterogeneity by the presence of visible infarction on 
CT in the effects of aspirin versus control on stroke 
recurrence in 31 072 adults after acute ischaemic stroke.16,17 
Randomised trials have not been done—but are needed—
to investigate the effects of antiplatelet therapy after 
intracerebral haemorrhage according to brain imaging 
features of intracerebral haemorrhage or cerebral small 
vessel diseases.18
In the REstart or STop Antithrombotics Randomised 
Trial (RESTART), survivors of intracerebral haemorrhage 
that occurred while taking antithrombotic therapy who 
were randomly allocated to start antiplatelet therapy had 
fewer recurrences of symptomatic intra cerebral haem­
orrhage over a median follow­up of 2·0 years than did 
those allocated to avoid antiplatelet therapy (12 [4%] of 
268 vs 23 [9%] of 268, respectively; adjusted hazard ratio 
[HR] 0·51, 95% CI 0·25–1·03; p=0·060).19 In a prespecified 
primary subgroup analysis, there was no evidence of 
heterogeneity of the effects of antiplatelet therapy on the 
primary outcome by in vestigators’ cate gorisation of lobar 
versus non­lobar intracerebral haem orrhage location 
(pinteraction=0·23).19 To further explore effects according to 
features of the intracerebral haemorrhage and cerebral 
small vessel diseases, we collected brain imaging per­
formed on all participants before randomisation, and did 
pri mary subgroup analyses of cerebral micro bleeds on 
MRI and exploratory subgroup analyses of other brain 
imaging features.
Research in context
Evidence before this study
Brain imaging features of intracerebral haemorrhage (such as 
lobar location) and brain imaging biomarkers of cerebral small 
vessel diseases (such as microbleeds or superficial siderosis) are 
associated with a higher risk of intracerebral haemorrhage 
recurrence. Consequently, some physicians withhold 
antiplatelet therapy from people with these imaging features. 
However, it is unclear whether the effects of antiplatelet 
therapy vary by these brain imaging features. We searched 
MEDLINE Ovid (from 1948), Embase Ovid (from 1980), and 
bibliographies of relevant publications on Feb 28, 2019, 
combining search terms for cerebral small vessel diseases, 
intracerebral haemorrhage, randomised controlled trials, 
antiplatelet therapy, and brain imaging in humans (appendix). 
There were no language restrictions. The SPS3 randomised 
controlled trial showed no heterogeneity by brain MRI features 
in the effects of aspirin and clopidogrel versus aspirin alone in 
1278 adults after subcortical ischaemic stroke. In the IST and 
CAST randomised controlled trials, there was no heterogeneity 
by visible infarction on brain CT in the effects of aspirin versus 
control in 31 072 adults after acute ischaemic stroke. However, 
no published randomised trials have reported the effects of 
antiplatelet therapy after intracerebral haemorrhage by brain 
imaging features.
Added value of this study
To our knowledge, RESTART is the first randomised controlled 
trial to investigate the effects of starting versus avoiding 
antiplatelet therapy in adults with previous intracerebral 
haemorrhage that occurred while taking antithrombotic 
(antiplatelet or anticoagulant) therapy, grouped by their brain 
imaging features. We did not find clinically or statistically 
significant hazardous effects of antiplatelet therapy on 
recurrent intracerebral haemorrhage or ischaemic stroke in 
primary subgroup analyses of cerebral microbleed presence, 
nor in any exploratory subgroup analyses of intracerebral 
haemorrhage location, previous vascular lesions, atrophy, 
periventricular lucencies, white matter hyperintensities, 
superficial siderosis, or diagnostic criteria for cerebral amyloid 
angiopathy.
Implications of all the available evidence
Our results exclude all but a very modest harmful effect of 
antiplatelet therapy on the primary outcome of recurrent 
intracerebral haemorrhage in the presence of cerebral 
microbleeds. Our findings provide information about the safety 
of antiplatelet therapy in subgroups of adults with intracerebral 
haemorrhage, although the precision of these analyses was 
limited by small sample size. The directions of the effects we 
have found permit the inclusion of adults with a wide range of 
brain imaging features in ongoing trials (RESTART-Fr, 
NCT02966119; and STATICH, NCT03186729) and future 
randomised controlled trials of antiplatelet therapy after 
intracerebral haemorrhage, which are likely to require sample 
sizes of more than 2200 participants to detect statistically 
significant interactions with treatment effects.
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Methods
Study design and participants
RESTART was an investigator­led, pragmatic, multicentre, 
prospective, randomised, open­label, blinded­endpoint, 
parallel­group trial in 122 hospitals in the UK. Participant 
eligibility, consent, data collection, monitoring, approvals, 
procedures, and statistical analysis principles are described 
in detail in the protocol,20 statistical analysis plan,21 and 
primary report of the trial.19
Briefly, patients were eligible for enrolment if they 
were aged 18 years or older, had survived at least 
24 h after spontaneous intracerebral haemorrhage, and 
were taking antithrombotic (antiplatelet or anticoagulant) 
therapy for the prevention of occlusive vascular disease 
at the onset of intracerebral haemorrhage, after which 
therapy was discontinued. Patients were ineligible if the 
intracerebral haemorrhage was attributable to preced­
ing head injury, haemorrhagic transformation of an 
ischaemic stroke, or intracranial haemorrhage without 
intracerebral haemorrhage; or if they were still taking 
antithrombotic therapy at the time of consent (ie, after 
intracerebral haemorrhage). Patients, or a representative, 
provided written informed consent in inpatient or out­
patient hospital settings. The Scotland A Research Ethics 
Committee approved the trial protocol.
Before randomisation, collaborators had to confirm that 
the brain imaging (usually CT, but sometimes MRI alone) 
that diagnosed the qualifying intracerebral haemorrhage 
was available and would be sent to the trial coordinating 
centre. Participants who had not already undergone brain 
MRI that complied with the trial’s imaging protocol, and 
who were able and willing to undergo brain MRI, provided 
informed consent for this to be performed. Details of the 
randomisation method and masking are described in the 
protocol and primary report of the trial.19,20
Procedures
The intervention of starting antiplatelet therapy was 
restricted to the use of one or more of oral aspirin, 
dipyridamole, or clopidogrel, begun within 24 h of 
randomisation. The comparator was a policy of avoiding 
antiplatelet therapy (ie, no placebo group).19,20
To be permitted to enrol participants in the MRI 
substudy, sites had to provide test imaging that passed 
image acquisition standards and adhered to the minimum 
requirements for sequences and parameters specified in 
the imaging protocol. Any field strength was permitted. 
Coverage from the very top of the vertex to the foramen 
magnum was essential. An axial gradient­recalled 
echo (GRE) T2* sequence was required with specified 
slice thickness (3 mm optimal, 3–5 mm acceptable), 
slice gap (none optimal, not more than 1 mm accept­
able), and echo time (20–30 ms optimal, 15–40 ms 
acceptable). The following MRI sequences were essential 
(although their sequence parameters were not specified): 
T1­weighted (volumetric preferred, otherwise sagittal), 
axial T2­weighted, axial diffusion­weighted imaging, and 
fluid­attenuated inversion recovery (axial preferred). 
Brain MRI was only included if acquired from participants 
before randomisation to avoid the possibility that the 
allocated treatment might affect appearances.
Investigators copied the earliest imaging study that 
diagnosed the qualifying intracerebral haemorrhage and 
any brain MRI substudy images that were obtained before 
randomisation in Digital Imaging and Communications 
in Medicine (DICOM) format, removed personal identi­
fiers and replaced these with a participant’s study number 
(pseudo­anonymisation), and sent the images to the trial 
coordinating centre after randomisation.
The RESTART imaging manager checked each imaging 
study to ensure that the participant, timing, and modality 
corresponded to the information provided before ran­
domisation. Each brain MRI study was checked to ensure 
that all the required sequences had been provided, using 
acceptable parameters. After quality assurance, all CT and 
MRI studies were uploaded to an electronic archive and 
Figure 1: Profile of imaging substudies within RESTART
537 participants randomly assigned 
 (268 to start antiplatelet therapy and 269 to avoid 
 antiplatelet therapy)
12 excluded from imaging subgroup analyses 
     (no intracerebral haemorrhage)
 5 haemorrhagic transformation of ischaemic stroke
 3 subarachnoid haemorrhage alone
 3 intraventricular haemorrhage alone
 1 meningioma
525 eligible participants with intracerebral haemorrhage
271 ineligible for brain 
 MRI substudy
 244 MRI never performed
 3 unable to tolerate MRI
 1 MRI not readable
 23 MRI not performed 
 according to imaging 
 protocol
18 ineligible for brain CT
 substudy (brain MRI first
 diagnosed intracerebral 
 haemorrhage)
252 assigned 
         to start 
         antiplatelet 
 therapy
 100 lobar
507 included in brain CT substudy 254 included in brain MRI substudy 
255 assigned 
         to avoid 
         antiplatelet  
 therapy
 102 lobar
122 assigned 
         to start 
         antiplatelet  
 therapy
 52 lobar
132 assigned 
         to avoid 
         antiplatelet  
 therapy
 56 lobar
506 included in analysis 254 included in analysis 
1 withdrew 
 from 
 follow-up
For the imaging protocol see 
http://www.restarttrial.org/
documents/RESTART_MRI_
protocol.pdf
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allocated to one of a panel of consultant neuroradiolo­
gists via the in­house, web­based, systematic image review 
system for confirmation and characterisation of brain 
imaging features of intracerebral haemorrhage diagnosis 
and cerebral small vessel diseases.1,22
A member of the independent panel of consult ant 
neuroradiologist adjudicators reviewed all imaging 
masked to treatment allocation before the trial data base 
was locked and the randomisation code was broken.20 
The panel member checked eligibility of each par­
ticipant by confirming that each imaging study 
demonstrated parenchymal haemorrhage, consistent 
with the given date of symptom onset, most likely due 
to intracerebral haemorrhage and not due to haemor ­
rhagic transformation of ischaemic stroke. If the inde­
pendent rating of the imaging studies did not 
con firm the existence of intra cerebral haemorrhage, 
another member of the panel re­reviewed all relevant 
imaging studies and made a final determination of 
eligibility.
For CT imaging, the neuroradiologist used validated 
scales to rate features of the single (or largest, if multiple) 
intracerebral haemorrhage (side, location, volume in 
mL measured by the ABC/2 method,23 intraventricular 
extension, subarachnoid extension, and subdural exten­
sion), the surrounding brain (previous vascular les­
ions22,24 and periventricular lucencies [leuko araiosis]25), 
and atrophy.22,26 One neuroradiologist rated the features 
of acute intracerebral haemor rhages with a lobar epicentre 
(subarachnoid extension and finger­like projections) to 
estimate the probability of underlying cerebral amyloid 
angiopathy according to the CT­only version of the 
Edinburgh diagnostic criteria.2
For MRI, the neuroradiologist used validated scales 
to rate features of the single (or largest, if multiple) 
intracerebral haemorrhage (side, location, volume in mL 
mea sured by the ABC/2 method,23 intraventricular exten­
sion, subarachnoid extension, and subdural exten sion), 
the surrounding brain (previous vascular lesions—ie, 
previous infarcts or previous haemorrhages that were 
not microbleeds),1,27 superficial siderosis (focal or dis­
seminated),3 white matter hyperintensities of pre sumed 
vascular origin,28 basal ganglia mineral de posits, en­
larged perivascular spaces, atrophy,29 and cerebral micro­
bleed presence, number, and location,30,31 as defined 
previously.1
Outcomes
The RESTART trial’s primary outcome (fatal or non­
fatal radiographi cally or pathologically proven recurrent 
sympto matic intracerebral haemorrhage) and secondary 
outcomes have been reported elsewhere.19 For this re­
port, we analysed eligible participants with intracerebral 
haemorrhage according to their treatment allocation 
in primary subgroup analyses of presence, burden, 
and location of cerebral microbleeds on MRI and 
in exploratory subgroup analyses of other brain imag­
ing features on CT or MRI. The secondary outcome 
in the subgroup analyses of brain imaging features 
was ischaemic stroke. Outcomes were ascertained and 
adjudicated as described in the protocol and primary 
report of the trial.19,20
Start antiplatelet 
therapy (n=252)
Avoid antiplatelet 
therapy (n=255)
Participant characteristics
Sex
Female 89 (35%) 79 (31%)
Male 163 (65%) 176 (69%)
Age (years) 77 (69–83) 76 (70–82)
Number of intracerebral haemorrhages
One 235 (93%) 242 (95%)
More than one 17 (7%) 13 (5%)
Characteristics of the largest intracerebral haemorrhage
Side
Left 120 (48%) 117 (46%)
Right 132 (52%) 138 (54%)
Location
Deep 123 (49%) 123 (48%)
Infratentorial 29 (12%) 30 (12%)
Lobar 100 (40%) 102 (40%)
Volume of largest intracerebral 
haemorrhage (mL)
3·7 (1·1–10·8) 4·3 (1·2–11·6)
Intraventricular extension 55 (22%) 70 (27%)
Subarachnoid extension 42 (17%) 50 (20%)
Subdural extension 6 (2%) 8 (3%)
Edinburgh CT-only criteria2 for acute intracerebral haemorrhages with 
lobar epicentres (n=499)*
Non-lobar intracerebral 
haemorrhage
152 (61%) 153 (61%)
Lower probability of cerebral 
amyloid angiopathy
83 (33%) 82 (33%)
High probability of cerebral 
amyloid angiopathy
14 (6%) 15 (6%)
Characteristics of the brain
Previous vascular lesions
No 98 (39%) 93 (36%)
Yes 154 (61%) 162 (64%)
Periventricular lucencies score†
0–2 165 (65%) 147 (58%)
3–4 87 (35%) 108 (42%)
Atrophy score‡
0–2 215 (85%) 212 (83%)
3–4 37 (15%) 43 (17%)
Data are n (%) or median (IQR). *Eight participants whose first brain CT showed 
subacute intracerebral haemorrhage (which precluded accurate rating of brain 
imaging features of the haemorrhage) were excluded. Start antiplatelet therapy, 
n=249; avoid antiplatelet therapy, n=250. High probability of cerebral amyloid 
angiopathy is defined as finger-like projections and subarachnoid extension; 
lower probability is all other features. †Periventricular lucencies score combines 
both anterior and posterior white matter scores (0=no lucency; 1=lucency 
restricted to region adjoining ventricles; 2=lucency covering entire region from 
lateral ventricle to cortex). ‡Atrophy score combines both central and cortical 
atrophy (each scored 0=none; 1=moderate; 2=severe).
Table 1: Baseline characteristics of participants in the CT substudy
For more on the systematic 
image review system tool see 
https://sirs2.ccbs.ed.ac.uk
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Statistical analysis
In our protocol and statistical analysis plan,20,21 we 
prespecified that the MRI substudy would focus on 
primary subgroup analyses, testing whether there was 
heterogeneity in the effects of antiplatelet therapy on the 
trial’s primary outcome of recurrent intracerebral haem­
orrhage by the presence, number, or location of cerebral 
microbleeds. We collected other brain imaging features 
on MRI and CT for exploratory subgroup analyses of the 
effects of antiplatelet therapy on recurrent intracere­
bral haemorrhage or ischaemic stroke. We present the 
analyses of CT imaging features first because of their 
larger sample size, but focus our reporting on the 
primary subgroup analyses of cerebral microbleeds on 
brain MRI.
We intended to obtain diagnostic imaging studies 
for all participants and recruit approximately 75% of 
RESTART participants to the MRI substudy, although 
ultimately investigators recruited a smaller total number 
and proportion of all participants, diminishing the 
precision of our findings. In RESTART, brain imaging 
was not always done despite consent being obtained; was 
not always provided; was performed but might have 
contravened the required protocol; was performed, but 
might have been degraded by motion artefact; or was 
performed but demonstrated that the patient was 
ineligible for inclusion in RESTART (which precluded 
collection of ratings by the RESTART imaging panel). We 
quantified these exclusions, retaining participants in the 
imaging analyses if pre­randomisation brain imaging 
was obtained (and was compliant with the RESTART 
protocol in the case of MRI), was readable, and confirmed 
intracerebral haemorrhage. We recorded the timing of 
imaging (symptom onset to earliest imaging study and 
earliest imaging study to randomisation).
We focused descriptive analyses on imaging features of 
primary interest at a meeting between RA­SS, PMW, and 
JMW before database lock and unmasking the trial 
database. We chose not to analyse other features at this 
time (basal ganglia mineral deposits and enlarged 
perivascular spaces on MRI). We also agreed on pragmatic 
categorisations of some complex variables (eg, previous 
vascular lesions, periventricular lucencies, and atrophy) 
based on previous experience of simplifying the complex 
rating scales of these features for analysis.1,2,17,22,24,26,29
We prespecified that cerebral microbleed presence was 
two or more microbleeds (in view of inter­rater variation 
in the reporting of solitary microbleeds30,31) and that 
microbleed location would be grouped as strictly lobar 
versus other, for dichotomous analysis of the presence of 
cerebral microbleeds on MRI. We prespecified that for 
categorical analysis of cerebral microbleed number, the 
split would be 0 or 1 versus 2–4 versus 5 or more.21 We 
investigated whether cerebral microbleed presence and 
Figure 2: Prespecified exploratory subgroup analyses of the risk of first recurrent symptomatic intracerebral haemorrhage (the primary outcome) by 
brain CT features
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burden (as a continuous variable) were associated, as 
expected,7,32 with the first recurrent intracerebral haem­
orrhage or ischaemic stroke in Cox proportional hazards 
regression models adjusted for the five covariates in the 
minimisation algorithm (qualifying intracerebral haem­
orrhage location, time since symptom onset, antiplatelet 
therapy preferred by the participant’s physician if 
allocated to start, participant age at randomisation, and 
predicted probability of being alive and independent at 
6 months). We analysed heterogeneity of the effects of 
antiplatelet therapy on the first recurrent intracerebral 
haemorrhage between subgroups using a statistical test 
of interaction, by including an interaction term between 
treatment group and each imaging feature in Cox 
proportional hazards regression models adjusted for the 
five covariates in the minimisation algorithm. We applied 
the Firth correction to Cox proportional hazards models in 
which we observed monotone likelihoods and calculated 
HRs with 95% profile likelihood confidence limits.33 The 
unmasked trial statistician performed statistical analyses 
with SAS, version 9.4.
The trial is registered with the ISRCTN registry, 
number ISRCTN71907627.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all data in the study and had final responsibility for the 
decision to submit for publication.
Results
Between May 22, 2013, and May 31, 2018, 537 participants 
were enrolled in the RESTART trial and randomly 
assigned to start antiplatelet therapy (n=268) or to avoid 
antiplatelet therapy (n=269), of whom 12 were inelig ible 
for the imaging subgroup analyses because their intra­
cranial haemorrhage did not extend into the brain 
parenchyma (figure 1). 18 participants were diagnosed 
using MRI alone, leaving 507 in the brain CT substudy. 
Start antiplatelet 
therapy (n=122)
Avoid antiplatelet 
therapy (n=132)
Participant characteristics
Sex
Female 42 (34%) 36 (27%)
Male 80 (66%) 96 (73%)
Age (years) 76 (70–81) 75 (69–82)
Number of intracerebral haemorrhages
One 117 (96%) 124 (94%)
More than one 5 (4%) 8 (6%)
Characteristics of the largest intracerebral haemorrhage
Side
Left 56 (46%) 59 (45%)
Right 66 (54%) 73 (55%)
Location
Deep 53 (43%) 66 (50%)
Infratentorial 17 (14%) 10 (8%)
Lobar 52 (43%) 56 (42%)
Volume of largest intracerebral 
haemorrhage (mL)
2·3 (0·4–7·9) 1·6 (0·4–7·1)
Intraventricular extension 10 (8%) 13 (10%)
Subarachnoid extension 17 (14%) 26 (20%)
Subdural extension 2 (2%) 8 (6%)
(Table 2 continues in next column)
Start antiplatelet 
therapy (n=122)
Avoid antiplatelet 
therapy (n=132)
(Continued from previous column)
Characteristics of the brain
Previous ischaemic lesions
None 72 (59%) 74 (56%)
One 18 (15%) 25 (19%)
More than one 32 (26%) 33 (25%)
Previous haemorrhagic lesions (that are not cerebral microbleeds)
None 110 (90%) 112 (85%)
One 12 (10%) 18 (14%)
More than one 0 2 (2%)
Superficial siderosis
None 95 (78%) 99 (75%)
Focal 19 (16%) 23 (17%)
Disseminated 8 (7%) 10 (8%)
White matter hyperintensities score*
0–2 39 (32%) 43 (33%)
3–6 83 (68%) 89 (67%)
Atrophy score†
0–2 76 (62%) 71 (54%)
3–4 46 (38%) 61 (46%)
Cerebral microbleeds (n=235)‡
Presence
0–1 66 (58%) 76 (63%)
2–4 16 (14%) 15 (12%)
5 or more 32 (28%) 30 (25%)
Location§
Strictly lobar 7 (15%) 13 (29%)
Other 41 (85%) 32 (71%)
Modified Boston criteria3 for participants with ratings for microbleeds 
and superficial siderosis
Probable cerebral amyloid 
angiopathy
19 (17%) 28 (23%)
Possible cerebral amyloid 
angiopathy
14 (12%) 16 (13%)
Neither probable nor 
possible cerebral amyloid 
angiopathy
81 (71%) 77 (64%)
Data are n (%) or median (IQR). *White matter hyperintensities score combines 
periventricular and deep (subcortical) white matter (each scored as 0, 1, 2, or 3). 
†Atrophy score combines central and cortical (each scored 0=none; 1=moderate; 
2=severe). ‡235 participants had an MRI sequence of sufficient quality to rate 
cerebral microbleeds; start antiplatelet therapy, n=114; avoid antiplatelet therapy, 
n=121. §Denominators are start antiplatelet therapy, n=48; avoid antiplatelet 
therapy, n=45. 
Table 2: Baseline characteristics of participants in the MRI substudy
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271 participants did not undergo per­protocol MRI, 
leaving 254 in the brain MRI substudy.
In the brain CT substudy, the median time from 
symptom onset to earliest CT was 0 days (IQR 0–1) and 
the median time from earliest CT to randomisation 
was 74 days (27–144). The age and sex distributions of 
participants included in the CT substudy were similar to 
those of participants in the whole trial (table 1).19 Most 
participants had a solitary intracerebral haemorrhage, 
40% of which were lobar. After excluding eight participants 
whose first brain CT showed subacute intracerebral 
haemorrhage (which precluded accurate rating of brain 
imaging features of the haemorrhage2), 305 had non­lobar 
haemorrhage and the remaining 194 participants with CT 
of acute intracerebral haemorrhage with a lobar epicentre 
were rated for the probability of underlying cerebral 
amyloid angiopathy according to the Edinburgh diagnostic 
criteria:2 29 (6%) of 499 participants had a high probability 
(finger­like projections and subarachnoid extension) and 
165 (33%) had a lower probability. Participants’ brains 
commonly showed previous vascular lesions (316 [62%] 
of 507), severe periventricular lucencies (195 [38%]), 
and moderate­to­severe atrophy (80 [16%]). There were 
small baseline imbalances in intraventricular extension, 
subarachnoid extension, and periventricular lucencies 
(table 1). One participant in the avoid antiplatelet therapy 
group of the brain CT substudy withdrew from follow­up 
and was not included in the analyses.
Figure 3: Prespecified primary and exploratory subgroup analyses of the risk of first recurrent symptomatic intracerebral haemorrhage (the primary 
outcome) by brain MRI features
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In prespecified exploratory subgroup analyses of CT 
features, we did not find strong evidence of statistically 
significant heterogeneity in the effects of antiplatelet 
therapy on recurrent intracerebral haemorrhage (figure 2) 
or ischaemic stroke (appendix) by intracerebral haem­
orrhage location, previous vascular lesions, periventric­
ular lucencies, atrophy, or the probability of underlying 
cerebral amyloid angiopathy.
In the brain MRI substudy, the median time from 
symptom onset to MRI was 55 days (IQR 18–102) and the 
median time from MRI to randomisation was 2 days 
(0–18). The age and sex distributions of participants 
included in the MRI substudy were similar to those of 
participants in the whole trial (table 2).19 108 (43%) of 
254 substudy participants had lobar intracerebral haemor­
rhage and 235 (93%) had a GRE T2* MRI sequence of 
sufficient quality to rate cerebral microbleeds: 93 (40%) of 
235 had two or more microbleeds, 62 (26%) of 235 had 
five or more microbleeds, and 20 (22%) of 93 had strictly 
lobar microbleeds, such that 47 (20%) of 235 probably had 
cere bral amyloid angiopathy and 30 (13%) of 235 possibly 
had cerebral amyloid angiopathy according to the 
modified Boston criteria.3 Background brain character­
istics on MRI (table 2) were very similar to characteristics 
on CT (table 1). There were small baseline imbalances in 
sex, intracerebral haemorrhage location and extension, 
atrophy, and cerebral microbleed strictly lobar location 
(table 2).
As was expected in this population,7,32 in the primary 
subgroup of 235 participants with cerebral microbleeds, 
their presence (2 or more versus 0 or 1) and burden (linear 
trend of 0 or 1, 2–4, and 5 or more) were associated 
with first recurrent intracerebral haemorrhage (adjusted 
HR 3·62 [95% CI 1·34–9·79] and 1·99 [1·20–3·31], 
respectively) and ischaemic stroke (HR 1·92 [0·83–4·46] 
and 1·62 [1·03–2·55], respectively; appendix).
We did not find clinically or statistically significant 
hazardous effects of antiplatelet therapy on recurrent 
intracerebral haemorrhage in any primary subgroup 
analyses of cerebral microbleed presence versus absence 
(HR 0·30 [95% CI 0·08–1·13] vs 0·77 [0·13–4·61]; 
pinteraction=0·41), cerebral microbleed number 0–1 versus 
2–4 versus 5 or more (HR 0·77 [0·13–4·62] vs 
0·32 [0·03–3·66] vs 0·33 [0·07–1·60]; pinteraction=0·75), or 
strictly lobar versus other location (HR 0·52 [0·004–6·79] 
vs 0·37 [0·09–1·28]; pinteraction=0·85; figure 3).
In prespecified exploratory subgroup analyses of other 
MRI features, we did not find strong evidence of statistic­
ally significant heterogeneity in the effects of antiplatelet 
therapy on recurrent intracerebral haemorrhage (figure 3) 
or ischaemic stroke (appendix; all pinteraction>0·05).
Discussion
In these subgroup analyses of the RESTART trial, the 
estimated effect of antiplatelet therapy in the subgroup 
with cerebral microbleeds (HR 0·30, 95% CI 0·08–1·13) 
excluded all but a very modest harmful effect of antiplatelet 
therapy on the primary outcome of recurrent intracerebral 
haemorrhage. Moreover, we did not find strong evidence 
of any significant heterogeneity of the effects of antiplate­
let therapy on recurrent intracerebral haemorrhage or 
ischaemic stroke in exploratory subgroup analyses of 
other CT or MRI features of the intracerebral haemorrhage 
or cerebral small vessel diseases.
Although caution is needed in the interpretation of 
non­significant differences between small subgroups,14 
we did not find strong evidence within the primary 
subgroup analyses of cerebral microbleeds that was 
consistent with the five­times greater risk of recurrent 
lobar intracerebral haemorrhage associated with aspirin 
use in people with cerebral microbleeds as seen in an 
observational study,5 which has hitherto influenced 
clinical practice.9,34 Furthermore, we did not find strong 
evidence of differences within exploratory subgroup 
analyses to suggest that superficial siderosis or diagnostic 
criteria for cerebral amyloid angiopathy might modify 
the risk of intracerebral haemorrhage with antiplatelet 
therapy.5,35 Although these brain imaging features are 
associated with higher absolute risks of intracerebral 
haemorrhage recurrence in observational studies,6,7 we 
did not find strong evidence that there was heterogeneity 
in the effects of antiplatelet therapy in these subgroups.
To our knowledge, RESTART is the first randomised 
trial comparing starting versus avoiding antiplatelet 
therapy after intracerebral haemorrhage to explore 
whether the effects of antiplatelet therapy vary by imag­
ing features of intracerebral haemorrhage or cerebral 
small vessel diseases. The main strengths of the trial are 
described elsewhere.19 The additional strengths of the 
imaging substudies are that they relied on imaging 
acquired before randomisation (so appearances could 
not have been affected by allocated treatment), imaging 
was performed in everyday clinical practice, MRI was 
done according to a standardised protocol, imaging was 
collected centrally in DICOM format, and adjudicated by 
experienced neuroradiologists masked to treatment 
allocation and outcome using validated rating scales.
The overall characteristics of participants in the trial 
were similar to those of patients in observational 
hospital­based studies of antiplatelet therapy use after 
intracerebral haemorrhage in clinical practice.5,19 
However, the external validity of our findings can be 
judged by participants’ imaging characteristics, which 
reflect the inclusion of survivors with haemorrhages 
that were smaller and had a lower prevalence of 
subarachnoid and intraventricular extension than those 
in all­inclusive population­based studies.2,36 Therefore, 
our findings are generalisable to adults who survived a 
median of 76 days after intracerebral haemorrhage, 
most of whom had good functional ability and few of 
whom had a low probability of good functional outcome 
at 6 months,19 in part because of the volumes of their 
intracerebral haemorrhages, which were smaller than 
those in population­based studies.2,36
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The sample size resulted in some small baseline 
imbalances. The numbers of outcomes were not large 
enough to detect small or modest differences between 
subgroups, in particular those brain imaging features that 
have been proposed to modify the effects of antiplatelet 
therapy, such as cerebral microbleeds and superficial 
siderosis.5,10,13 However, the extent of heterogeneity in the 
effects of antiplatelet therapy after intracerebral haem­
orrhage by brain imaging features was unknown before 
the trial started, so we could not accurately estimate the 
sample sizes required to adequately power our subgroup 
analyses.
In clinical practice, physicians and patients might be 
reassured by our finding that excluded all but a very 
modest harmful effect of antiplatelet therapy on recurrent 
intracerebral haemorrhage in the presence of brain 
microbleeds. This finding might encourage changes to 
the current risk­averse approach of not using anti­
platelet therapy after intracerebral haemorrhage, driven 
by findings from a small observational study.5,9,10,34 More­
over, there was no strong evidence of heterogeneity 
between subgroups, and the effect estimates in almost all 
sub groups were consistent with the trial’s overall finding 
that antiplatelet therapy might reduce the risk of recurrent 
intracerebral haemorrhage. Furthermore, despite the 
association between superficial siderosis and recurrent 
intracerebral haemorrhage,6 the effect of antiplatelet 
therapy on recurrent intracere bral haemorrhage in people 
with superficial siderosis (HR 0·70, 95% CI 0·17–2·93) 
might affect clinical equipoise and increase recruitment 
of people with this imaging feature in future randomised 
trials of antithrombotic therapies.
The directions and magnitudes of the effects we 
have found should help to inform the precision of 
sub group analyses in imaging substudies in on going 
trials (RESTART­Fr, NCT02966119; and STATICH, 
NCT03186729) and future randomised controlled trials of 
antithrombotic therapy after intracerebral haemorrhage. 
These randomised trials are needed to investigate our 
findings with greater precision. It is a frequent mis­
conception that risk factors for stroke recurrence in 
observational studies, such as cerebral microbleeds,7,32 are 
also modifiers of the effects of antithrombotic therapies, 
although this can only be investigated in randomised 
controlled trials with larger sample sizes.
Our findings provide the opportunity to estimate 
the minimum sample size that would be required to 
demonstrate a potentially statistically significant sub group 
interaction with the effects of antiplatelet therapy in this 
population. If we assume that having more periventricular 
lucencies causes a four­times greater risk of recurrent 
intracerebral haemorrhage (HR 0·19 [95% CI 0·04–0·86] 
for 0–2 periventricular lucencies vs 0·89 [0·35–2·23] 
for 3–4; pinteraction=0·089), then to detect such an interact ion 
in a future parallel­group randomised trial, assuming 
similar event rates over 2 years of follow­up, with 
90% power at the 5% significance level, a sample size of 
at least 2200 participants would be needed (or at least 
3000 participants at the 1% significance level).
In summary, we excluded all but a very modest harmful 
effect of antiplatelet therapy on recurrent intracerebral 
haemorrhage in the presence of brain microbleeds and 
we did not find strong evidence of heterogeneity in the 
effects of antiplatelet therapy by other brain imaging 
features. Further randomised trials are needed to repli­
cate these findings and investigate them with greater 
precision.
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